LaiK.N., TangS.C.W., LeungJ.C.K.Mediators of inflammation and fibrosis.Perit Dial Int2007; 27(Suppl 2): S65–71.
4.
SelgasR., BajoA., Jimenez-HeffernanJ.A., Sanchez-TomeroJ.A., Del PesoG., AguileraA.Epithelial-to-mesenchymal transition of mesothelial cell—its role in the response of the peritoneum to dialysis.Nephrol Dial Transplant2006; 21(Suppl 2): ii2–7.
5.
NohH., HaH., YuM.R., KimY.O., KimJ.H., LeeH.B.Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species.Perit Dial Int2005; 25: 38–47.
6.
DumanS., BozkurtD., SipahiS., SezakM., OzkanS., ErtilavM.The effects of everolimus, as an antiproliferative agent, on regression of the encapsulated peritoneal sclerosis model.Adv Perit Dial2008; 24: 104–10.
7.
YaoQ., AyalaE.R., QianJ.Q., StenvinkelP., AxelssonJ., LindholmB.A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.Clin Nephrol2007; 68: 295–301.
8.
LafranceJ.P., LétourneauI., OuimetD., BonnardeauxA., LeblancM., MathieuN.Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy.Am J Kidney Dis2008; 51: e7–10.
